Ítem
Acceso Abierto

Cost-effectiveness analysis of iStent trabecular microbypass stent for patients with open-angle glaucoma in Colombia

Mostrar el registro sencillo de la publicación
dc.contributor.advisorOrdoñez, Jaime
dc.creatorOsorio, Urpy
dc.creatorOrdoñez, Angelica
dc.creator.degreeMagíster en Administración en Salud
dc.date.accessioned2018-04-20T22:14:07Z
dc.date.available2018-04-20T22:14:07Z
dc.date.created2018-02-26
dc.date.issued2018
dc.description.abstractObjective: To estimate cost-effectiveness of trabecular micro bypass stent versus laser trabeculoplasty or medications only, for patients with open-angle glaucoma in setting of Colombian System Health. Methods: This is a cost-effectiveness analysis that based its assumptions in external data sources, used to extrapolate the quality of life related to health, survival and costs. A Markov model, with stages from 0 (ocular hypertension without glaucoma) to 5 and bilateral blindness, was developed inclusive of Colombian older than 40 years in 2018, from a societal perspective, comparing trabecular micro-bypass stents versus, laser trabeculoplasty, timolol+dorzolamide+brimonidine, timolol+dorzolamide+latanoprost, or timolol+dorzolamide+brimatoprost, in terms of clinical and economic outcomes over a lifetime horizon. Both costs and health outcomes had an annual rate discount of 5%. Health outcomes were evaluated in terms of QALYs related with loss of visual acuity. Trabecular micro-bypass costs include the joint use of timolol, the costs of laser trabeculoplasty include the combined use of timolol+dorzolamide. Results: Trabecular micro-bypass stents were estimated to have 127,971 more discounted QALYs, versus laser trabeculoplasty; 405,982, versus timolol+dorzolamide+brimonidine; and 378,287, versus timolol+dorzolamide+latanoprost or timolol+dorzolamide+brimatoprost. Cumulative costs with trabecular micro-bypass stents at 40 years was $13,252,318 lower than laser trabeculoplasty; $6,403,534, lower than timolol+dorzolamide+brimonidine; $22,311,064, lower than timolol+dorzolamide+latanoprost; and $29,156,113 lower than timolol+dorzolamide+brimatoprost. Conclusions: Trabecular micro-bypass stent is a highly cost-saving strategy due to more QALYs related to a lower rate of the population with loss of visual acuity in the long term, and because the costs associated with additional medications and complications are lower with trabecular micro-bypass stents.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.48713/10336_17928
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/17928
dc.language.isospa
dc.publisherUniversidad del Rosariospa
dc.publisher.departmentFacultad de administraciónspa
dc.publisher.programMaestría en Administración en Saludspa
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombiaspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.source.bibliographicCitationBeidoe G, Mousa SA. Current primary open-angle glaucoma treatments and future directions. Clin Ophthalmol. 2012; 6: 1699-707.
dc.source.bibliographicCitationTham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis.
dc.source.bibliographicCitationCedrone C, Mancino R, Cerulli A, Cesareo M, Nucci C. Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects. Prog Brain Res. 2008; 173: 3-14
dc.source.bibliographicCitationViaña JM, Pongo L, Castro H, Corbera JC. Incidencia del glaucoma en la región Grau. Rev peruana Oftalmol. 1995; 19: 23-5
dc.source.bibliographicCitationArieta CE, de Oliveira DF, Lupinacci AP, Novaes P, Paccola M, Jose NK, Limburg H. Cataract remains an important cause of blindness in Campinas, Brazil. Ophthalmic Epidemiology. 2009; 16(1): 58-63
dc.source.bibliographicCitationSalomao SR, Cinoto RW, Berezovsky A, Araujo-Filho A, Mitsuhiro MR, Mendieta L, et al. Prevalence and causes of vision impairment and blindness in older adults in Brazil: the Sao Paulo Eye Study. Ophthalmic Epidemiology. 2008; 15(3): 167-75
dc.source.bibliographicCitationCass H, Landers J, Benitez P. Causes of blindness among hospital outpatients in Ecuador. Clin Exp Ophthalmol. 2006; 34(2): 146-51
dc.source.bibliographicCitationMinisterio de Salud y Protección Social, Organización Panamericana de la Salud. Análisis de situación de situación de salud visual en Colombia. Bogotá DC: Ministerio de Salud y Protección Social; 2016
dc.source.bibliographicCitationJonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017; 390(10108): 2183-93.
dc.source.bibliographicCitationMinisterio de Salud y Protección Social. Resolución 5269 de 2017, by which the Health Benefits Plan is updated with charge to the Capitation Payment Unit (UPC, by its acronym in Spanish) (22 Dec 2017)
dc.source.bibliographicCitationSaheb H, Ahmed IIK. Micro-invasive glaucoma surgery: current perspectives and future directions. Current Opin Ophthalmol. 2012; 23(2): 96–104
dc.source.bibliographicCitationPrum Jr BE, Lim MC, Mansberger SL, Stein JD, Moroi SE, Gedde SJ, et al. Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern® Guidelines. Ophthalmology.2016; 123(1):P112-P51
dc.source.bibliographicCitationHenderer JD, Rapuano CJ. Ocular Pharmacology. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e. New York, NY: McGraw-Hill Education; 2011
dc.source.bibliographicCitationDocherty JR. Subtypes of functional aplha1-adrenoceptor. Cell Mol Life Sci. 2010; 67(3): 405-17
dc.source.bibliographicCitationBecker B. The effects of the carbonic anhydrase inhibitor, acetazoleamide, on the composition of the aqueous humor. Am J Ophthalmol. 1955; 40(5 Pt 2): 129-36
dc.source.bibliographicCitationEpstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Serum chemical analysis. Arch Ophthalmol. 1977; 95(8): 1378-82
dc.source.bibliographicCitationZimmerman TJ. Pilocarpine. Ophthalmology. 1981; 88(1): 85-8.
dc.source.bibliographicCitationRolim de Moura C, Paranhos A Jr, Wormald R. Laser trabeculoplasty for open angle glaucoma. Cochrane Database Syst Rev. 2007; (4): CD003919.
dc.source.bibliographicCitationArriola-Villalobos P, Martinez-de-la-Casa JM, Diaz-Valle D, Morales-Fernandez L, Fernandez-Perez C, Garcia-Feijoo J. Glaukos iStent inject® trabecular micro-bypass implantation associated with cataract surgery in patients with coexisting cataract and open-angle glaucoma or ocular hypertension: a long-term study. J Ophthalmol. 2016; 2016: 1056573
dc.source.bibliographicCitationInstituto de Evaluación Tecnológica en Salud. Manual para la elaboración de evaluaciones económicas en salud. Bogotá D.C.: IETS, 2014
dc.source.bibliographicCitationOck M, Han JW, Lee JY, Kim SH, Jo MW. Estimating quality-adjusted life-year loss due to noncommunicable diseases in Korean adults through to the year 2040. Value Health.2015;18(1):61-6
dc.source.bibliographicCitationAtkins D, Eccles M, Flottorp S, Guyatt GH, Henry D; GRADE Working Group, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004; 4(1): 38
dc.source.bibliographicCitationMills RP, Budenz DL, Lee PP, Noecker RJ, Walt JG, Siegartel LR, et al. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. Am J Ophthalmol. 2006; 141(1): 24-30
dc.source.bibliographicCitationTinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. N Engl J Med. 1988; 319(26): 1701-7
dc.source.bibliographicCitationStevens JA, Rudd RA. Circumstances and contributing causes of fall deaths among persons aged 65 and older: United States, 2010. J Am Geriatr Soc. 2014; 62(3): 470-5
dc.source.bibliographicCitationYuki K, Asaoka R, Tsubota K. Investigating the influence of visual function and systemic risk factors on falls and injurious falls in glaucoma using the structural equation modelling. PLoS One. 2015; 10(6): e0129316
dc.source.bibliographicCitationSkalska A, Wizner B, Piotrowicz K, Klich-Rączka A, Klimek E, Mossakowska M, et al. The prevalence of falls and their relation to visual and hearing impairments among a nation-wide cohort of older Poles. Exp Gerontol. 2013; 48(2): 140-6
dc.source.bibliographicCitationHong T, Mitchell P, Burlutsky G, Samarawickrama C, Wang JJ. Visual impairment and the incidence of falls and fractures among older people: longitudinal findings from the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci. 2014; 55(11): 7589-93.
dc.source.bibliographicCitationDirani M, Crowston JG, Taylor PS, Moore PT, Rogers S, Pezzullo Ml, et al. Economic impact of primary open-angle glaucoma in Australia. Clin Exp Ophthalmol. 2011; 39(7): 623-32.
dc.source.bibliographicCitationLin CH, Liao KC, Pu SJ, Chen YC, Liu MS. Associated factors for falls among the community-dwelling older people assessed y annual geriatric health examinations. PLos One. 2011; 6(4): e18976
dc.source.bibliographicCitationLord SR, Dayhew J. Visual risk factors for falls in older people. J Am Geriatr Soc. 2001; 49(5): 508-15.
dc.source.bibliographicCitationOsterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353(5): 487-97
dc.source.bibliographicCitationvan der Valk R, Webers CA, Lumley T, Hendrikse F, Prins MH, Schouten JS. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol. 2009; 62(12): 1279-83
dc.source.bibliographicCitationLin L, Zhao YJ, Chew PT, Sng CC, Wong HT, Yip LW, et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014; 48(12): 1585-93
dc.source.bibliographicCitationBrandt JD, Cantor LB, Katz LJ, Batoosingh Al, Chou C, Bossowska I; Ganfort Investigators Group II. Bimatoprost/timolol fixed combination: a 3-month double masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008; 17(3): 211-6
dc.source.bibliographicCitationCraven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R; Combigan Study Group. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2005; 21(4): 337-48.
dc.source.bibliographicCitationSilver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol. 1998; 126(3): 400-8
dc.source.bibliographicCitationBucci MG. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma. 1999; 8(1): 24-30.
dc.source.bibliographicCitationCentofanti M, Oddone F, Vetrugno M, Manni G, Fogagnolo P, Tanga L, et al. Efficacy of the fixed combinations of bimatroprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator masked, clinical study. Eur J Ophthalmol. 2009; 19(1): 66-71.
dc.source.bibliographicCitationHigginbotham EJ, Olander KW, Kim EE, Grunden JW, Kwok KK; United States Fixed Combination Study, et al. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol. 2010; 128(2): 165-72.
dc.source.bibliographicCitationHoy SM, Keam SJ, Keating GM. Tavoprosto/timolol. Drugs Aging. 2006; 23(7): 587-97.
dc.source.bibliographicCitationSchuman JS, Katz GJ, Lewis RA, Henry JC, Mallick S, Wells DT, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005; 140(2): 242-50
dc.source.bibliographicCitationSacchi M, Specchia C, Williams SE, Villani E, Nucci P. Efficacy of bimatoprost plus timolol fixed combination in open angle glaucoma patients previously treated with dorzolamide plus timolol fixed combination. Curr Eye Res. 2016; 41(11): 1433-7
dc.source.bibliographicCitationKonstas AG, Voudouragkaki IC, Boboridis KG, Haidich AB, Paschalinou E, Giannopoulos T, et al. 24-hour efficacy of travoprost/timolol BAK-free versus latanoprost/timolol fixed combinations in patients insufficiently controlled with latanoprost. Adv Ther. 2014; 31(6):592-603
dc.source.bibliographicCitationHartleben-Matkin C, Prada D, Mancilla-Vences R. A 4-year retrospective study of add on therapy to the fixed combination of dorzolamide/timolol for the treatment of POAG. Int J Ophthalmol. 2014; 7(2): 330-4
dc.source.bibliographicCitationLesk MR, Koulis t, Sampalis F, Sampalis JS, Bastien NR. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Ann Pharmacother. 2006; 42(4): 498-504
dc.source.bibliographicCitationMichaud JE, Friren B; International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001; 132(2): 235-43.
dc.source.bibliographicCitationSolish AM, DeLucca PT, Cassel DA, Kolodny AH, Hustad CM, Skobieranda F. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma. 2007; 2004; 13(2): 149-57.
dc.source.bibliographicCitationGreig SL, Deeks ED. Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension. Drugs Aging. 2015; 32(3): 251-60
dc.source.bibliographicCitationSharma S, Trikha S, Perera SA, Aung T. Clinical effectiveness of brinzolamide 1% brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2015; 9: 2201-7
dc.source.bibliographicCitationThe Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Glaucoma Laser Trial Research Group. Am J Ophthalmol. 1995; 120(6): 718-31.
dc.source.bibliographicCitationRolim de Moura C, Paranhos A Jr, Wormald R. Laser trabeculoplasty for open angle glaucoma. Cochrane Database Syst Rev. 2007; (4): CD003919
dc.source.bibliographicCitationSpiegel D, Wetzel W, Neuhann T, Stuermer J, Hoeh H, Garcia-Feijoo J, et al. Coexistent primary open-angle glaucoma and cataract: interim analysis of a trabecular micro-bypass stent and concurrent cataract surgery. Eur J Ophthalmol. 2009; 19(3): 393-9.
dc.source.bibliographicCitationOkeke CO, Quigley HA, Jampel HD, Ying GS, Plyler RJ, Jiang Y, Friedman DS. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patient. Ophthalmology. 2009; 116(12): 2289-93
dc.source.bibliographicCitationGupta R, Patil B, Shah BM, Bali, Mishra SK, Dada T. Evaluating eye drop instillation technique in glaucoma patients. J Glaucoma. 2012; 21(3): 189-92.
dc.source.bibliographicCitationCampbell JH, Schwartz G, Labounty B, Kowalski J, Patel VD. Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions. Curr Med Res Opin. 2013; 29(9): 1201-9
dc.source.bibliographicCitationBarnebey HS, Robin AL. Adherence to fixed-combination versus unfixed travoprost 0.004%/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol. 2017; 176: 61-9
dc.source.bibliographicCitationLee PP, Walt JG, Doyle JJ, Kotak SV, Evans SJ, Budenz DL, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol. 2006; 124(1): 12-9
dc.source.bibliographicCitationWeinreb RN, Friedman DS, Fechtner DS, Fechtner RD, Cioffi GA, Coleman AL, Girkin CA, et al. Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol. 2004; 138(3): 458-67
dc.source.bibliographicCitationLee BS, Kymes SM, Nease RF Jr, Sumner W, Siegfried CJ, Gordon MO. The impact of anchor points on utilities for 5 common ophthalmic diseases. Ophthalmology. 2008; 115(5): 898-903
dc.source.bibliographicCitationKatsoulis M, Benetou V, Karapetyan T, Feskanich D, Grodstein F, Pettersson-Kymmer U, et al. Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project. J Intern Med. 2017; 281(13): 300-10
dc.source.bibliographicCitationDepartamento Administrativo Nacional de Estadística (DANE). Proyecciones nacionales y departamentales de población 2005-2020. Bogotá D.C.: DANE, 2010.
dc.source.bibliographicCitationBerdahl JP, Khatana AK, Katz LJ, Herndon L, Layton AJ, Yu TM, et al. Cost comparison of two trabecular micro-bypass stents versus selective laser trabeculoplasty or medication only for intraocular pressure control for patients with open-angle glaucoma. J Med Econ. 2017; 20(7): 760-6.
dc.source.bibliographicCitationPizzi LT, Waisbourd M, Hark L, Sembhi H, Lee P, Crews JE, et al. Costs of a community-based glaucoma detection programme: analysis of the Philadelphia Glaucoma Detection and Treatment Project. Br J Ophthalmol. 2017 Jun 27. pii: bjophthalmol-2016 310078.
dc.source.bibliographicCitationJavanbakht M, Azuara-Blanco A, Burr JM, Ramsay C, Cooper D, Cochran C, et al. Early lens extraction with intraocular lens implantation for the treatment of primary angle closure glaucoma: an economic evaluation on data from the EAGLE trial. BMJ Open. 2017; 7(1): e013254.
dc.source.bibliographicCitationBoodhna T, Crabb DP. More frequent, more costly? Health economic modelling aspects of monitoring glaucoma patients in England. BMC Health Serv Res. 2016; 16(1): 611
dc.source.bibliographicCitationKaplan RI, De Moraes CG, Cioffi GA, Al-Aswad LA, Blumberg DM. Comparative cost effectiveness of the Baerveldt implant, trabeculectomy with mitomycin, and medical treatment. JAMA Ophthalmol. 2015; 133(5):560-7
dc.source.bibliographicCitationPatel HY, Wagschal LD, Trope GE, Buys YM. Economic analysis of the Ex-PRESS miniature glaucoma device versus trabeculectomy. J Glaucoma. 2014; 23(6): 385-90.
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subjectCost-benefit analysisspa
dc.subjectOpen-angle glaucomaspa
dc.subjectOcular hypertensionspa
dc.subjectStentsspa
dc.subjectMinimally invasive surgical proceduresspa
dc.subjectMedication adherencespa
dc.subject.ddcVarias ramas de la medicina, Cirugía
dc.subject.decsGlaucoma de Ángulo Abiertospa
dc.subject.decsHipertensión Ocularspa
dc.subject.decsStentsspa
dc.subject.decsProcedimientos Quirúrgicos Mínimamente Invasivosspa
dc.subject.decsCumplimiento de la Medicaciónspa
dc.subject.decsAnálisis Costo-Beneficiospa
dc.titleCost-effectiveness analysis of iStent trabecular microbypass stent for patients with open-angle glaucoma in Colombiaspa
dc.typemasterThesiseng
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.type.spaTesis de maestríaspa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
OsorioRodriguez-UrpyMayra-2018.pdf
Tamaño:
2.67 MB
Formato:
Adobe Portable Document Format
Descripción:
Documento Principal
Descargar
Colecciones
Maestría en Administración en Salud